Pharma RSS Digest - 2026-05-21
Overview
Thursday's session reflects a light news cycle with two substantively different catalysts: a late-stage biotech win for a rare pediatric indication and a serious medical device safety action. BioMarin's positive Phase 3 readout for VOXZOGO in hypochondroplasia marks the drug's expansion beyond its existing achondroplasia approval, potentially opening a new commercial frontier with no direct competition. Meanwhile, the FDA's Class I designation for Bolton Medical's Relay Pro stent-graft system underscores persistent risk in the thoracic aortic device space, with three reported deaths prompting immediate removal from the market. Both stories carry regulatory and commercial implications worth tracking into next week.
Key Developments
BioMarin VOXZOGO passes Phase 3 in hypochondroplasia, FDA filing planned for Q3
BioMarin announced May 20 that its CANOPY-HCH-3 Phase 3 trial met the primary endpoint in children ages 3–17 with hypochondroplasia, showing a +2.33 cm/year improvement in annualized growth velocity versus placebo (p<0.0001). Secondary endpoints including standing height, height Z-score, and arm span also reached statistical significance at 52 weeks. The safety profile showed no new signals relative to the established achondroplasia dataset. The company plans to submit a supplemental New Drug Application to the FDA in Q3 2026, followed by filings to the EMA and other health authorities.
BioMarin clinical trial update
The readout matters because hypochondroplasia currently has no approved therapies in the U.S. or European Union, leaving a clear unmet need for the often-toddler-diagnosed population. Success here validates the C-type natriuretic peptide mechanism beyond the already-approved achondroplasia indication, potentially broadening VOXZOGO's commercial footprint substantially. Market participants should monitor for the timing of the sNDA submission and any signals from FDA regarding priority review designation, as a Q3 filing could position an approval decision in late 2026 or early 2027.
Bolton Medical's Relay Pro stent-graft receives Class I recall after three deaths
The FDA classified a recall for Bolton Medical's Relay Pro Thoracic Stent-Graft System as Class I on May 20, 2026, following an Early Alert issued April 28. The device's proximal clasp can detach, preventing graft release and necessitating open-surgery conversion in some cases. Three patient deaths have been reported—one from aortic perforation and two from fatal strokes during conversion surgery. The recall covers N4 non-bare stent configurations of 32mm and above, which have been removed from use and sale. Bolton Medical now operates under Terumo Aortic.
The recall matters because the Relay Pro is a widely used minimally invasive option for thoracic aortic aneurysms, dissections, and transections. Its removal narrows the therapeutic toolkit for vascular surgeons and leaves hospitals to pivot to alternative graft options, potentially accelerating market share shifts among competitors. Watch for any update from Terumo Aortic regarding a replacement or redesign timeline, and monitor whether additional adverse events emerge as the recall propagates through clinical workflows.
Watchlist
- BioMarin: Full dataset presentation from CANOPY-HCH-3 at upcoming medical meeting; FDA filing confirmation in Q3. [link]
- Terumo Aortic / Bolton Medical: Updated communication to hospitals on affected inventory and patient monitoring protocols. [link]
- FDA: Any further Class I actions or safety communications from other device manufacturers in the vascular space.